Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of RBD5044 in Healthy Subjects
NCT05539651Phase 1Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rbd5044 in hypertriglyceridemia and mixed dyslipidemia (4 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0. Started Nov 2022; status: completed.
02
Drugs
rbd5044
03
Conditions
hypertriglyceridemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT05539651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539651.